308 related articles for article (PubMed ID: 23630281)
1. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.
Mahlknecht G; Maron R; Mancini M; Schechter B; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2013 May; 110(20):8170-5. PubMed ID: 23630281
[TBL] [Abstract][Full Text] [Related]
2. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.
Mahlknecht G; Sela M; Yarden Y
Methods Mol Biol; 2015; 1317():3-15. PubMed ID: 26072398
[TBL] [Abstract][Full Text] [Related]
3. An Intelligent DNA Nanorobot with
Ma W; Zhan Y; Zhang Y; Shao X; Xie X; Mao C; Cui W; Li Q; Shi J; Li J; Fan C; Lin Y
Nano Lett; 2019 Jul; 19(7):4505-4517. PubMed ID: 31185573
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of HER2 expression with an 18F-fluoride labeled aptamer.
Kim HJ; Park JY; Lee TS; Song IH; Cho YL; Chae JR; Kang H; Lim JH; Lee JH; Kang WJ
PLoS One; 2019; 14(1):e0211047. PubMed ID: 30682091
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs.
Lee H; Dam DH; Ha JW; Yue J; Odom TW
ACS Nano; 2015 Oct; 9(10):9859-67. PubMed ID: 26335372
[TBL] [Abstract][Full Text] [Related]
6. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
Sett A; Borthakur BB; Bora U
Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
[TBL] [Abstract][Full Text] [Related]
7. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.
Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
9. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
[TBL] [Abstract][Full Text] [Related]
10. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
Zhang DX; Zhao PT; Xia L; Liu LL; Liang J; Zhai HH; Zhang HB; Guo XG; Wu KC; Xu YM; Jia LT; Yang AG; Chen SY; Fan DM
Gut; 2010 Mar; 59(3):292-9. PubMed ID: 19951902
[TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
13. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
14. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers.
Varmira K; Hosseinimehr SJ; Noaparast Z; Abedi SM
J Drug Target; 2014 Feb; 22(2):116-22. PubMed ID: 24098950
[TBL] [Abstract][Full Text] [Related]
15. Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding.
Mahlknecht G; Maron R; Schechter B; Yarden Y; Sela M
Biochem Biophys Res Commun; 2015 Sep; 465(2):218-24. PubMed ID: 26248137
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial Screening of DNA Aptamers for Molecular Imaging of HER2 in Cancer.
Zhu G; Zhang H; Jacobson O; Wang Z; Chen H; Yang X; Niu G; Chen X
Bioconjug Chem; 2017 Apr; 28(4):1068-1075. PubMed ID: 28122449
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
19. Revealing the molecular interactions of aptamers that specifically bind to the extracellular domain of HER2 cancer biomarker protein: An in silico assessment.
Niazi S; Purohit M; Sonawani A; Niazi JH
J Mol Graph Model; 2018 Aug; 83():112-121. PubMed ID: 29902673
[TBL] [Abstract][Full Text] [Related]
20. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.
Dastjerdi K; Tabar GH; Dehghani H; Haghparast A
Biotechnol Appl Biochem; 2011; 58(4):226-30. PubMed ID: 21838796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
